Vitamin D Deficiency and Supplementation in Human Metabolic Diseases

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Micronutrients and Human Health".

Deadline for manuscript submissions: 25 May 2024 | Viewed by 3037

Special Issue Editors


E-Mail Website
Guest Editor
Division of Endocrinology and Diabetology, Medical University of Graz, 8036 Graz, Austria
Interests: intensive care; endocrinology; vitamin D; hypoparathyroidism; iron deficiency; women in science
Special Issues, Collections and Topics in MDPI journals

E-Mail Website1 Website2
Guest Editor
Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Interests: endocrinology; osteology; diabetes

E-Mail Website1 Website2
Co-Guest Editor
Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
Interests: vitamin D; vitamin

Special Issue Information

Dear Colleagues,

Vitamin D is an important steroid hormone for human skeletal and non-skeletal health. There are many risk groups for vitamin D deficiency in the general population, specifically in patients with chronic diseases. However, there is still controversy regarding the true value of vitamin D from both sides: those who argue that a sufficient amount of vitamin D will prevent most diseases, and those who argue that vitamin D is overrated. The truth lies between these two extremes; therefore, it is important to continue with high-quality research and work on strategies for universally implementing the facts that we already know into clinical routine.

In this Special Issue, we are looking for original reports, systematic reviews, meta-analyses, cost-effectiveness analyses, and even extraordinary case reports on the topic of vitamin D deficiency and supplementation in human metabolic diseases (including, but not limited to, prediabetes, metabolic syndrome, obesity, hypo- and hyperparathyroidism, and thyroid disease). We are also interested in effect size analyses, public health strategies, and fortification strategies across the globe and are looking forward to receiving high-quality submissions that will undergo a fair but strict review process.

Dr. Karin Amrein
Dr. Astrid Fahrleitner-Pammer
Dr. Christina Geiger
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vitamin D (active/native)
  • prediabetes
  • metabolic syndrome
  • obesity
  • parathyroid disease
  • thyroid disease
  • effect size
  • meta-analysis
  • public health strategies
  • fortification

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 466 KiB  
Article
Impact of Intravenous Iron Substitution on Serum Phosphate Levels and Bone Turnover Markers—An Open-Label Pilot Study
by Alexandra Struppe, Jakob E. Schanda, Andreas Baierl, Paul Watzl and Christian Muschitz
Nutrients 2023, 15(12), 2693; https://0-doi-org.brum.beds.ac.uk/10.3390/nu15122693 - 09 Jun 2023
Viewed by 1388
Abstract
The association between intravenous iron substitution therapy and hypophosphatemia was previously reported in patients with iron deficiency anemia. However, the extent of hypophosphatemia is thought to depend on the type of iron supplementation. We hypothesized that the intravenous application of ferric carboxymaltose and [...] Read more.
The association between intravenous iron substitution therapy and hypophosphatemia was previously reported in patients with iron deficiency anemia. However, the extent of hypophosphatemia is thought to depend on the type of iron supplementation. We hypothesized that the intravenous application of ferric carboxymaltose and iron sucrose leads to a different longitudinal adaptation in serum phosphate levels. In this open-label pilot study, a total of 20 patients with inflammatory bowel diseases or iron deficiency anemia were randomly assigned to one of two study groups (group 1: ferric carboxymaltose, n = 10; group 2: iron sucrose, n = 10). Serum values were controlled before iron substitution therapy, as well as 2, 4, and 12 weeks after the last drug administration. The primary objective of the study was the longitudinal evaluation of serum phosphate levels after iron substitution therapy with ferric carboxymaltose and iron sucrose. The secondary objective was the longitudinal investigation of calcium, 25-hydroxyvitamin D (25(OH)D), intact parathyroid hormone, procollagen type 1 amino-terminal propeptide (P1NP), beta-CrossLaps (CTX), hemoglobin (Hb), iron, ferritin, and transferrin saturation levels. Two weeks after drug administration, phosphate levels were significantly lower (p < 0.001) in group 1 and ferritin levels were significantly higher (p < 0.001) in group 1. Phosphate levels (0.8–1.45 mmol/L) were below the therapeutic threshold and ferritin levels (10–200 ng/mL for women and 30–300 ng/mL for men) were above the therapeutic threshold in group 1. P1NP (15–59 µg/L) and CTX (<0.57 ng/mL) levels were above the therapeutic threshold in group 2. Four weeks after drug administration, significant differences were still observed between both study groups for phosphate (p = 0.043) and ferritin (p = 0.0009). All serum values except for Hb were within the therapeutic thresholds. Twelve weeks after drug administration, no differences were observed in all serum values between both study groups. Hb values were within the therapeutic threshold in both study groups. Serum 25(OH)D levels did not differ between both study groups throughout the whole study period and remained within the therapeutic threshold. Full article
(This article belongs to the Special Issue Vitamin D Deficiency and Supplementation in Human Metabolic Diseases)
Show Figures

Figure 1

10 pages, 273 KiB  
Article
Vitamin D Deficiency and Carotid Media-Intima Thickness in Childhood Cancer Survivors
by Eryk Latoch, Kacper Kozłowski, Katarzyna Konończuk, Beata Żelazowska-Rutkowska, Monika Tomczuk-Ostapczuk, Maryna Krawczuk-Rybak and Katarzyna Muszyńska-Rosłan
Nutrients 2023, 15(10), 2333; https://0-doi-org.brum.beds.ac.uk/10.3390/nu15102333 - 16 May 2023
Viewed by 1183
Abstract
Childhood cancer survivors (CCS) are predisposed to developing numerous late effects of anticancer treatment later in life. The existing literature suggests that vitamin D deficiency (VDD) may influence cardiovascular abnormalities and metabolic diseases. The objectives of this study were to investigate the prevalence [...] Read more.
Childhood cancer survivors (CCS) are predisposed to developing numerous late effects of anticancer treatment later in life. The existing literature suggests that vitamin D deficiency (VDD) may influence cardiovascular abnormalities and metabolic diseases. The objectives of this study were to investigate the prevalence of VDD among childhood cancer survivors and examine the association of vitamin D deficiency and carotid intima-media thickness (IMT). The study comprised 111 childhood cancer survivors (62 males, 49 females) with a median follow-up time of 6.14 years. Vitamin D status was determined by measuring serum 25(OH)D levels using the automatic immunoenzymatic method. Ultrasonography of the common carotid artery (CCA), the carotid bulb, and the proximal part of the internal carotid artery (ICA) was conducted. Vitamin D deficiency (<20 ng/mL) was detected in 69.4% of CCS. A higher parathormone level and increased BMI were observed among VDD survivors. No effects of type of diagnosis, radiotherapy or hematopoietic stem cell transplantation on vitamin D status were observed. Our findings reveal that survivors with VDD exhibited significantly greater thickness in the CCA and carotid bulb. In conclusion, the results of our study of childhood cancer survivors demonstrate that vitamin D deficiency is prevalent in up to 70% of individuals. We did not confirm the hypothesis that factors related to anticancer treatment used during childhood contributed to the higher prevalence of VDD. Additionally, we did not verify the contribution of vitamin D deficiency to the increase in IMT thickness. Full article
(This article belongs to the Special Issue Vitamin D Deficiency and Supplementation in Human Metabolic Diseases)
Back to TopTop